Pellucid marginal degeneration (PMD) is an eye condition that has been around for a long time, but is still relatively unknown and poorly understood. PMD is a progressive, non-inflammatory condition that causes thinning of the cornea at the outer edge, or margin, of the eye. This can lead to decreased vision, light sensitivity, and other vision-related problems. The exact cause of PMD is unknown, but it is thought to be related to genetics, environmental factors, or a combination of both. In this article, we will explore the mysteries of PMD, discuss the symptoms, diagnosis, and treatment options, and provide an overview of the current research.
Pellucid marginal degeneration (PMD) is a progressive, non-inflammatory eye disease that affects the peripheral cornea. It is characterized by thinning of the cornea at the outer edge, or margin, of the eye. This thinning can cause decreased vision, light sensitivity, and other vision-related problems. PMD is most commonly seen in people between the ages of 20 and 40, although it can occur at any age.
The most common symptom of PMD is decreased vision in the affected eye. This can range from mild to severe, depending on the severity of the condition. Other symptoms may include light sensitivity, glare, halos around lights, double vision, and astigmatism. In some cases, the condition may also cause pain or discomfort.
PMD is typically diagnosed during a comprehensive eye exam. During the exam, the doctor will look for signs of thinning of the cornea at the outer edge of the eye. They may also use a slit lamp to examine the cornea more closely. Imaging tests, such as OCT (optical coherence tomography) or ultrasound, may also be used to confirm the diagnosis.
Treatment of PMD is aimed at relieving symptoms and preserving vision. In most cases, this can be done with glasses, contact lenses, or surgery. In severe cases, corneal transplantation may be necessary.
Currently, there is limited research on PMD, and the exact cause of the condition is unknown. However, researchers believe that genetics, environmental factors, or a combination of both may play a role. Studies have also suggested that PMD may be associated with certain autoimmune diseases, such as rheumatoid arthritis.
Pellucid marginal degeneration is a progressive, non-inflammatory eye condition that can cause decreased vision, light sensitivity, and other vision-related problems. Although the exact cause of PMD is unknown, it is thought to be related to genetics, environmental factors, or a combination of both. Treatment of PMD is aimed at relieving symptoms and preserving vision, and can include glasses, contact lenses, or surgery. Research on PMD is ongoing, and further studies are needed to better understand the condition and develop more effective treatments.
1.
Non-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care
2.
FDA approves Blenrep for relapsed or refractory multiple myeloma
3.
X-ray and radar technology combined to reduce cancer screening risks
4.
Extended Maintenance with Imatinib Enhances Disease-Free Survival in High-Risk GIST.
5.
Researchers discuss HER2-low and HER2-zero in breast cancer
1.
Understanding Mesenteric Masses: Symptoms, Diagnosis, and Treatment Options
2.
Liposomal Doxorubicin and Mitomycin in Modern Cancer Treatment
3.
The New Era of Oncology: Key Updates and Clinical Insights
4.
HIPEC in Platinum-Sensitive Ovarian Cancer: A Promising Yet Controversial Option
5.
Theranostics and Radioligand Therapy: Precision Cancer Care with Targeted Radionuclides
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial
2.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I
3.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation